Jeffrey H. Burbank '86, founder and chief executive officer of NxStage Medical, Inc. has been appointed to CryoLife, Inc.’s board of directors. His new position became effective September 29, 2017.
CryoLife is a leading company in manufacturing, processing and distributing implantable living tissues and medical devices. Their efforts are focused on cardiac and vascular surgery.
Burbank earned a bachelor’s in industrial engineering from Lehigh University. Since graduating, he gained experience with companies providing products for the treatment of end-stage renal disease (ESRD) and acute kidney failure.
NxStage is a leader in medical technology that develops, manufactures and markets products for the treatment of ESRD. He has led the company since its founding in 1998, guiding it through its developmental phases, product line extension and expansion into various markets.
“Jeff has over 30 years of in-depth management experience in medical devices, highlighted by his tenure growing NxStage Medical from inception to more than $360 million in annual revenue,” said Pat Mackin, who is chairman, president and CEO of CryoLife. “His experience will allow him to bring a unique perspective to our Board on our internal and external development programs. Jeff brings a proven track record of success to the board as we continue to focus on accelerating the company's growth."
Burbank is an inventor on over 50 U.S. patents for medical devices. Prior to NxStage, Burbank co-founded Vasca, Inc. in 1996, where he served as its chairman, chief executive officer and president. He worked for nine years at Gambro, Inc., serving as director of marketing and advanced technologies in its renal division. Burbank was also the director of operations at ZymeQuest and an executive board member of the National Kidney Foundation.
"I am excited to join the CryoLife Board of Directors,” Burbank said. “I share the Company's vision to advance the standard of care with innovative products that help improve the health and quality of life of patients. I look forward to working with Pat, the board and the CryoLife team as they continue to advance the company's mission."
OCTOBER 4, 2017